Last reviewed 2026-04-22 · How we verify

COV155

COV155 is a selective norepinephrine reuptake inhibitor that increases norepinephrine levels in the central nervous system.

COV155 is a selective norepinephrine reuptake inhibitor that increases norepinephrine levels in the central nervous system. Used for Attention-deficit/hyperactivity disorder (ADHD).

At a glance

Mechanism of action

By blocking the reuptake of norepinephrine at the presynaptic neuron, COV155 increases norepinephrine availability in synaptic spaces, enhancing noradrenergic neurotransmission. This mechanism is intended to improve attention, focus, and other cognitive or behavioral symptoms in conditions where noradrenergic dysfunction is implicated.

Approved indications

• Attention-deficit/hyperactivity disorder (ADHD)

Common side effects

• Increased heart rate
• Elevated blood pressure
• Insomnia
• Headache
• Dry mouth

Key clinical trials

• Pharmacokinetic, Bioavailability, and Safety Study of COV155 Administered in Healthy Subjects Under Fed and Fasted Conditions (PHASE1)
• Safety and Efficacy Study of COV155 for Post-operative Bunionectomy Pain (PHASE3)
• Pharmacokinetic, Bioavailability, and Safety Study of COV155 Administered in Healthy Subjects Under Fed and Fasted Conditions (PHASE1)
• Open Label Safety and Tolerability Study of COV155 in Subjects With Osteoarthritis (OA) or Chronic Low Back Pain (CLBP) (PHASE3)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• COV155 CI brief — competitive landscape report
• COV155 updates RSS · CI watch RSS
• Mallinckrodt portfolio CI